Ofer Purim, MD

Head, Gastrointestinal Malignancy Unit, Shaare Zedek Medical Center

Appears in 1 story

Stories

Experimental gel that reverses EGFR-inhibitor rash meets Phase 2 endpoints

Presented earlier Phase 2 data at ESMO GI 2025

Colorectal cancer patients on EGFR inhibitors often develop painful, cherry-red acneiform rashes. A third of them cut back or pause their cancer therapy because of it. Lutris Pharma's experimental gel reduced that non-adherence rate to 10.3%, down from 28.2% with placebo, in a 118-patient Phase 2 trial.

Updated 2 hours ago